-
tricision's independently developed Survivin-TargetingDendritic Cell (DC) Cell Injection has reached two major milestones inrapid succession: the Center for Drug Evaluation (CDE) haspublicly listed th -
When standard treatment options reach theirlimits, Clinical Trials (CTs) can offer a new ray of hope.This guide provides a clear roadmap for Glioblastoma Multiforme (GBM) patientsand their families on -
The immune system's ability to recognizeand eliminate cancer cells depends on tumor antigens—molecularmarkers that distinguish malignant cells from healthy tissue. These antigensdetermine whether the -
Glioblastoma Multiforme (GBM) is widely regarded as the "king of cancers"—arelentless and deadly adversary of the central nervous system. In China, theannual incidence is approximately 5–8 per 100,000 -
At the start of 2025, China's firstMessenger RNA-Dendritic Cell (mRNA-DC) tumor vaccine for primary GlioblastomaMultiforme (GBM) began enrolling patients in a Phase IClinical Trial (CT) at Beijing Tia -
On May 22, 2024, China ReformHealth and Beijing tricision Biotech Co., Ltd. (tricision) signed aStrategic Cooperation Agreement in Beijing—a milestone collaboration thatmarks a significant acceleratio -
The "Tri-Medicine SynergyFuture Healthcare Conference" took place in Shanghai on April12–13, co-hosted by China Reform Fund, China Reform Health Managementand Services Group Co., Ltd. (China Reform He -
On January 30, Beijing tricision Biotech Co., Ltd. (tricision) received the "Notification of Grant of Invention Patent Right" from the China National Intellectual Property Administration (CNIPA) for i -
At the start of 2024, the world'sfirst Survivin-targeting Messenger RNA-Dendritic Cell (mRNA-DC) tumor vaccine forthe treatment of Glioblastoma Multiforme (GBM), developed byBeijing tricision Biotech -
On December 8, the 8th "MakerChina" Beijing SME Innovation and Entrepreneurship Competition—also knownas "Maker Beijing 2023"—concluded successfully. Beijingtricision Biotech Co., Ltd. (tricision) was -
On November 7, the Office of the NationalHigh-Tech Enterprise Recognition and Management Leading Group released the"2023 First Batch of High-Tech Enterprise Recognition List forBeijing." Beijing trici -
Thermo Fisher Scientific Inc. (ThermoFisher) and Beijing tricision Biotech Co.,Ltd. (tricision) have signed a Memorandum of Understanding (MOU) for globalcommercial collaboration, building on their ex -
Beijing tricision Biotech Co., Ltd.(tricision) and China Resources Biopharmaceutical Co., Ltd. (ChinaResources Biopharmaceutical) have announced that YixingChenggong New Drug Development Co., Ltd. (Ch -
On February 20, the ChinaAssociation for Science and Technology (CAST) officially released theresults of its 2022 "Innovation China" series roster. Followingmultiple rounds of rigorous evaluation, Bei -
Recently, Beijing tricision Biotech Co.,Ltd. (tricision) and China Resources Biopharmaceutical Co., Ltd. (ChinaResources Biopharmaceutical) signed a strategic cooperation agreement tojointly develop a -
On January 10, the Center for DrugEvaluation (CDE) of the National Medical Products Administration (NMPA)announced on its official website that tricision's mRNA-DC vaccine forglioblastoma multiforme—S -
A multi-institutional study publishedin Nano Today, titled "A Highly EfficientNeedle-Free-Injection Delivery System for mRNA-LNP Vaccination againstSARS-CoV-2," was conducted by researchers from Capit -
Drug delivery has long been a majortechnical barrier in mRNA drug development. The rapid advancement of mRNAtechnology relies on interdisciplinary collaboration across biology, medicine,pharmacy, mate -
On June 5, 2022, at 10:44 AM, Chinalaunched the Shenzhou-14 manned spacecraft from the Jiuquan Satellite LaunchCenter using the Long March-2F Y14 rocket, carrying astronauts Chen Dong, LiuYang, and Ca -
Delivering mRNA drugs effectively into thehuman body is highly challenging. mRNA is a large, negatively chargedsingle-stranded molecule—and the cell membrane is also negatively charged,creating electr
一 About US
一 Research
一 Products & Service
一 Newsroom
